Agilent Technologies, Human Metabolome Technologies collaborate on metabolomics solution to speed disease and drug research
Agilent Technologies Inc. and Human Metabolome Technologies, a Japanese bioventure, announced they have signed an agreement to collaborate on an integrated set of metabolome analysis tools designed to help researchers discover potential therapeutics.
Under the agreement, the two companies will work to integrate HMT's novel biochemical assays with Agilent's capillary electrophoresis (CE) and mass spectrometry (MS) technologies for the profiling, identification and quantitation of metabolic markers. Metabolomics, which aims to characterize the complete set of metabolites, provides critical insights into how living things function under particular conditions, such as stress or disease, and may help identify targets for drug development. Typical human cells contain thousands of metabolites, and the aim of the HMT/Agilent solution is to develop a new and unique mass-spectrometry-based workflow for high throughput analysis.
"The human metabolome is the next frontier of research beyond the genome and the proteome, and metabolomics promises exciting advances," said Dr. Yoshihiro Ohtaki, president of HMT. "The combination of Agilent's robust and sensitive CE/MS technology with our latest metabolomics methodologies will speed the identification of metabolites and improve scientists' ability to map the human metabolome."
The Agilent and HMT metabolomics solution is expected to be on the market within six months.
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
More news from our other portals
See the theme worlds for related content
Topic World Mass Spectrometry
Mass spectrometry enables us to detect and identify molecules and reveal their structure. Whether in chemistry, biochemistry or forensics - mass spectrometry opens up unexpected insights into the composition of our world. Immerse yourself in the fascinating world of mass spectrometry!

Topic World Mass Spectrometry
Mass spectrometry enables us to detect and identify molecules and reveal their structure. Whether in chemistry, biochemistry or forensics - mass spectrometry opens up unexpected insights into the composition of our world. Immerse yourself in the fascinating world of mass spectrometry!
Last viewed contents
Applying quantitative proteomics to tumor marker discovery
Novel insights in MET-proto-oncogene might lead to optimizing cancer treatment - MET inhibitors could have a double-edged effect on tumors
Mosaiques and U.S. FDA sign contract for collaboration in discovery and validation of biomarkers for assessment of drug toxicity
Danny_Glover
LEUKOCARE has been granted both ISO 9001 and ISO 13485 certification
Alligator Bioscience enters into research and option agreement with BioInvent to jointly develop Antibody-based therapeutics
Seegene Receives Approval from Health Canada for Its Respiratory Virus Multi-Pathogen Detection Tests
MDxHealth establishes US CLIA laboratory in Irvine, CA, and makes key hires to expand US team
